Pharming Group Nv Stock Today
| PHGUF Stock | USD 0.75 0.07 8.54% |
Performance0 of 100
| Odds Of DistressLess than 10
|
Pharming Group is trading at 0.75 as of the 26th of November 2024. This is a 8.54 percent down since the beginning of the trading day. The stock's lowest day price was 0.75. Pharming Group has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Pharming Group NV are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of September 2024 and ending today, the 26th of November 2024. Click here to learn more.
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. Pharming Group N.V. The company has 652.41 M outstanding shares. More on Pharming Group NV
Moving against Pharming Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Pharming Pink Sheet Highlights
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Pharming Group NV [PHGUF] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Small-Cap' category with a current market capitalization of 880.76 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Pharming Group's market, we take the total number of its shares issued and multiply it by Pharming Group's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Pharming Group NV classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 652.41 M outstanding shares.
Pharming Group NV has accumulated about 189.96 M in cash with 37.84 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.29.
Check Pharming Group Probability Of Bankruptcy
Ownership AllocationPharming Group owns a total of 652.41 Million outstanding shares. Roughly 81.6 pct. of Pharming Group outstanding shares are held by general public with 1.97 % owned by insiders and only 16.43 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Pharming Ownership Details
Pharming Group NV Risk Profiles
| Mean Deviation | 0.6435 | |||
| Standard Deviation | 2.28 | |||
| Variance | 5.2 | |||
| Risk Adjusted Performance | (0.04) |
Pharming Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Pharming Group without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Dashboard Now
Portfolio DashboardPortfolio dashboard that provides centralized access to all your investments |
| All Next | Launch Module |
Pharming Group Corporate Management
| Bruno Giannetti | Member of the Management Board, Chief Operations Officer | Profile | |
| Susanne Embleton | Investor Mang | Profile | |
| Jeroen Wakkerman | Chief Officer | Profile | |
| Ruud Outersterp | Chief Officer | Profile | |
| Stephen Toor | Chief Americas | Profile | |
| Anurag Relan | Chief Officer | Profile | |
| MBA MD | CEO Pres | Profile |
Additional Information and Resources on Investing in Pharming Pink Sheet
When determining whether Pharming Group NV is a strong investment it is important to analyze Pharming Group's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pharming Group's future performance. For an informed investment choice regarding Pharming Pink Sheet, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pharming Group NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.